Qureshi A A, Shott S, Mallin B A, Gitelis S
Department of Orthopedic Surgery, Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois 66012-3824, USA.
J Bone Joint Surg Am. 2000 Aug;82(8):1122-31. doi: 10.2106/00004623-200008000-00009.
Adamantinoma of long bones is a rare tumor. Published reviews of the orthopaedic management of adamantinoma have involved limited follow-up of small numbers of patients. The oncological aggressiveness of this tumor is unknown. Limb salvage is currently the treatment of choice for most adamantinomas. The purpose of this study was to evaluate the characteristics of adamantinoma of long bones as well as the oncological outcome and the complications of limb salvage operations.
A retrospective study was designed to evaluate the clinical outcomes of limb salvage operations for the treatment of adamantinoma. Data on seventy biopsy-proven cases of adamantinoma treated between 1982 and 1992 at twenty-three different cancer centers in Europe and North America were obtained.
The median duration of follow-up was 7.0 years. The male:female ratio was 3:2, and the mean age was thirty-one years. Limb salvage was attempted in 91 percent (sixty-four) of the seventy patients, and the final rate of limb preservation was 84 percent (fifty-nine of seventy). Wide operative margins were obtained in 92 percent (fifty-eight) of sixty-three patients. An intercalary allograft was used to reconstruct the segmental bone defect in 51 percent (thirty-six) of the seventy patients. Reconstruction-related complications occurred in 48 percent (thirty) of sixty-two patients. Nonunion and fracture were the most common complications, occurring in 24 percent (fifteen) and 23 percent (fourteen) of sixty-two patients, respectively. Kaplan-Meier analysis demonstrated a rate of local recurrence of 18.6 percent at ten years. Wide operative margins were associated with a lower rate of local recurrence than marginal or intralesional margins were (p < 0.00005). Kaplan-Meier analysis showed a survival rate of 87.2 percent at ten years. There were no significant relationships between survival and the stage of the tumor (p = 0.058), duration of symptoms (p = 0.90), gender (p = 0.79), or wide operative margins (p = 0.14).
Current treatment of adamantinoma, including en bloc tumor resection with wide operative margins and limb salvage, provides lower rates of local recurrence than has been previously reported. In the present study, the limb preservation rate was 84 percent (fifty-nine of seventy), and the survival rate was 87.2 percent at ten years. The rate of complications related to the limb reconstruction was high.
长骨造釉细胞瘤是一种罕见的肿瘤。已发表的关于造釉细胞瘤骨科治疗的综述所涉及的患者数量有限且随访时间不足。这种肿瘤的肿瘤侵袭性尚不清楚。肢体挽救目前是大多数造釉细胞瘤的首选治疗方法。本研究的目的是评估长骨造釉细胞瘤的特征以及肢体挽救手术的肿瘤学结局和并发症。
设计了一项回顾性研究,以评估肢体挽救手术治疗造釉细胞瘤的临床结局。获取了1982年至1992年期间在欧洲和北美的23个不同癌症中心接受治疗的70例经活检证实的造釉细胞瘤病例的数据。
中位随访时间为7.0年。男女比例为3:2,平均年龄为31岁。70例患者中有91%(64例)尝试进行肢体挽救,最终肢体保留率为84%(70例中的59例)。63例患者中有92%(58例)获得了广泛的手术切缘。70例患者中有51%(36例)使用了节段性同种异体骨移植来重建节段性骨缺损。62例患者中有48%(30例)发生了与重建相关的并发症。骨不连和骨折是最常见的并发症,分别发生在62例患者中的24%(15例)和23%(14例)。Kaplan-Meier分析显示,10年时局部复发率为18.6%。与边缘或瘤内切缘相比,广泛的手术切缘与较低的局部复发率相关(p < 0.00005)。Kaplan-Meier分析显示,10年生存率为87.2%。生存率与肿瘤分期(p = 0.058)、症状持续时间(p = 0.90)、性别(p = 0.79)或广泛的手术切缘(p = 0.14)之间无显著关系。
目前造釉细胞瘤的治疗方法,包括采用广泛手术切缘的整块肿瘤切除和肢体挽救,其局部复发率低于先前报道。在本研究中,肢体保留率为84%(70例中的59例),10年生存率为87.2%。与肢体重建相关的并发症发生率较高。